» Articles » PMID: 29069581

Aligning Nanotoxicology with the 3Rs: What is Needed to Realise the Short, Medium and Long-term Opportunities?

Overview
Publisher Elsevier
Specialties Pharmacology
Toxicology
Date 2017 Oct 26
PMID 29069581
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Nanomaterials convey numerous advantages, and the past decade has seen a considerable rise in their development and production for an expanse of applications. While the potential advantages of nanomaterials are clear, concerns over the impact of human and environmental exposure exist. Concerted, science-led efforts are required to understand the effects of nanomaterial exposure and ensure that protection goals are met. There is much on-going discussion regarding how best to assess nanomaterial risk, particularly considering the large number of tests that may be required. A plethora of forms may need to be tested for each nanomaterial, and risk assessed throughout the life cycle, meaning numerous acute and chronic toxicity studies could be required, which is neither practical nor utilises the current evidence-base. Hence, there are scientific, business, ethical and legislative drivers to re-consider the use of animal toxicity tests. An expert Working Group of regulators, academics and industry scientists were gathered by the UK's NC3Rs to discuss: i) opportunities being offered in the short, medium and long-terms to advance nanosafety, ii) how to align these advances with the application of the 3Rs in nanomaterial safety testing, and iii) shifting the focus of risk assessment from current hazard-based approaches towards exposure-driven approaches.

Citing Articles

Predicting tissue distribution and tumor delivery of nanoparticles in mice using machine learning models.

Mi K, Chou W, Chen Q, Yuan L, Kamineni V, Kuchimanchi Y J Control Release. 2024; 374:219-229.

PMID: 39146980 PMC: 11886896. DOI: 10.1016/j.jconrel.2024.08.015.


Business Risk Mitigation in the Development Process of New Monoclonal Antibody Drug Conjugates for Cancer Treatment.

Kiss B, Borbely J Pharmaceutics. 2023; 15(6).

PMID: 37376209 PMC: 10304217. DOI: 10.3390/pharmaceutics15061761.


Daphnia as a model organism to probe biological responses to nanomaterials-from individual to population effects via adverse outcome pathways.

Reilly K, Ellis L, Davoudi H, Supian S, Maia M, Silva G Front Toxicol. 2023; 5:1178482.

PMID: 37124970 PMC: 10140508. DOI: 10.3389/ftox.2023.1178482.


Approach toward -Based Human Toxicity Effect Factors for the Life Cycle Impact Assessment of Inhaled Low-Solubility Particles.

Romeo D, Hischier R, Nowack B, Wick P Environ Sci Technol. 2022; 56(12):8552-8560.

PMID: 35657801 PMC: 9227749. DOI: 10.1021/acs.est.2c01816.


An investigation of the hepatic toxicity of PEGylated polymeric redox responsive nanoparticles.

Powell L, Alexander C, Stone V, Johnston H, Conte C RSC Adv. 2022; 12(20):12860-12870.

PMID: 35496338 PMC: 9044528. DOI: 10.1039/d2ra00395c.